Home > Healthcare > Pharmaceuticals > Disease Specific Drugs > Amyotrophic Lateral Sclerosis Treatment Market

Amyotrophic Lateral Sclerosis Treatment Market Size

Report ID: GMI11664
Published Date: Oct 2024
Report Format: PDF

Download Free Sample

Amyotrophic Lateral Sclerosis Treatment Market Size

The global amyotrophic lateral sclerosis treatment market size accounted for USD 713.3 million in 2023 and is projected to grow at a CAGR of 5.5% from 2024 to 2032. The growth of the market is driven by several key factors, including the rising prevalence of ALS, increased awareness, advancements in therapeutic technologies, and the development of novel treatment options.

To get key market trends

Download Free Sample

Additionally, the increasing incidence of ALS is significantly contributing to market growth. For instance, according to the National Institutes of Health (NIH), the number of ALS cases worldwide is projected to rise from 222,801 in 2015 to 376,674 by 2040, underscoring the urgent need for effective interventions and therapies.

Advancements in diagnostic technologies have also played a crucial role in the early detection and management of ALS. The introduction of advanced neuroimaging techniques, genetic testing, and biomarker research has enhanced healthcare professionals' ability to identify ALS at earlier stages, enabling timely and personalized treatment approaches, which in turn is driving the growth of the ALS treatment market.

Amyotrophic Lateral Sclerosis Treatment Market Report Attributes
Report Attribute	Details
Base Year:	2023
Amyotrophic Lateral Sclerosis Treatment Market Size in 2023:	USD 713.3 Million
Forecast Period:	2024 – 2032
Forecast Period 2024 – 2032 CAGR:	5.5%
2024 – 2032 Value Projection:	USD 1.1 Billion
Historical Data for:	2021 – 2023
Tables, Charts & Figures:	464
Segments covered:	Treatment Type, Disease Type, Route of Administration, End-use, and Region
Growth Drivers:	Rising prevalence of amyotrophic lateral sclerosis (ALS) globally Growing awareness and early diagnosis of ALS Development of novel drug therapies
Pitfalls & Challenges:	High cost associated with treatment Side effects associated with treatment

Learn more about the key segments shaping this market

Download Free Sample

Amyotrophic lateral sclerosis (ALS) is a progressive nervous system disease that affects nerve cells in the brain and spinal cord. Over time, ALS impairs the muscles necessary for movement, speech, eating, and breathing. ALS treatment involves the development, manufacturing, and distribution of therapeutic solutions. The market encompasses a wide range of products, including medications and stem cell therapies, alongside ongoing research into new treatments.

Authors: Mariam Faizullabhoy, Gauri Wani

Frequently Asked Questions (FAQ) :

The global market for amyotrophic lateral sclerosis treatments was valued at USD 713.3 million in 2023 and is projected to grow at a 5.5% CAGR from 2024 to 2032, driven by the rising incidence of ALS, increased awareness, advancements in therapeutic technologies, and the development of novel treatment options.

The market is segmented into medication, stem cell therapy, and other treatment types. In 2023, the medication segment dominated the market, accounting for USD 479.7 million.

The North American market for ALS treatments is expected to grow at a 5.2% CAGR, reaching USD 515.6 million by 2032. The U.S. represents a significant portion of this market, driven by the high prevalence of the disease and a robust healthcare infrastructure.

Prominent companies in the ALS treatment industry include AB Science, Biogen Inc., Biohaven Pharmaceutical (a subsidiary of Pfizer, Inc.), BrainStorm Therapeutics, Inc., Corestemchemon Inc., Eledon Pharmaceuticals, Inc., F. Hoffmann-La Roche Ltd, Ionis Pharmaceuticals, Inc., and ITF Pharma GmbH. These companies have either commercial drugs available or are in clinical development phases.